GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MannKind Corp (STU:NNFN) » Definitions » Notes Receivable

MannKind (STU:NNFN) Notes Receivable : €0.0 Mil (As of Mar. 2025)


View and export this data going back to . Start your Free Trial

What is MannKind Notes Receivable?

MannKind's Notes Receivable for the quarter that ended in Mar. 2025 was €0.0 Mil.


MannKind Notes Receivable Historical Data

The historical data trend for MannKind's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MannKind Notes Receivable Chart

MannKind Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

MannKind Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

MannKind Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


MannKind Notes Receivable Related Terms

Thank you for viewing the detailed overview of MannKind's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


MannKind Business Description

Traded in Other Exchanges
Address
1 Casper Street, Danbury, CT, USA, 06810
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.

MannKind Headlines

No Headlines